COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111
Summary
To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of subjects that are alive without respiratory failure at Day 22. Respiratory failure is defined as non-invasive ventilation or high-flow oxygen, intubation and mechanical ventilation, or ventilation with additional organ support (e.g., pressors, RRT, ECMO).
Timeline
- Start
- 2020-06-18
- Primary completion
- 2020-12-18
- Completion
- 2021-08-13
Outcome
Met primary endpoint
release “Primary efficacy endpoint in hospitalized patients shows VERU-111 treatment had statistically significant 81% relative reduction in death or respiratory failure at Day 29” verupharma.com ↗
release “For the primary endpoint in a modified intent-to-treat (MITT) population, VERU-111 treatment compared to placebo had a statistically significant” verupharma.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sabizabulin | Small molecule | 18 mg | Oral |